Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing
an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred …

Neoantigens generated by non-synonymous mutations of tumor genes can induce activation
of neoantigen-reactive T (NRT) cells which have the ability to resist the growth of tumors …

Cell adhesion involves many interactions between various molecules on the cell membrane
(receptors, coreceptors, integrins, etc.) and surfaces or other cells. Cell adhesion plays a …

Introduction Chimeric antigen receptor (CAR) T-cells have emerged as a ground-breaking
therapy for the treatment of hematological malignancies due to their capacity for rapid tumor …

No T cell receptor (TCR) T cell therapies have obtained clinical approval. The lack of
strategies capable of selecting and recovering potent T cell candidates may be a contributor …

Established and emergent microengineered in vitro systems enable the evaluation of
chimeric antigen receptor (CAR) T cell product purity, avidity, and functionality. Here, we …

Simple Summary There are multiple strategies to target cancer cells, and among the rapidly
evolving field is the use of bispecific antibodies and T-cell engagers in the treatment of …

Colon cancer (CC) has a poor 5-year survival rate though the treatment techniques and
strategies have been improved. Succinylation and long noncoding RNAs (lncRNAs) have …

CAR-T cell and T cell engager therapies have demonstrated transformational efficacy
against hematological malignancies, but achieving efficacy in solid tumors has been more …

Background Advanced clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer
for which long-term survival rates are abysmal, though immunotherapies are showing …